<DOC>
	<DOCNO>NCT01903837</DOCNO>
	<brief_summary>This Phase 2 , randomize , placebo-controlled multicenter study , conduct 2 part . The study duration subject approximately 33 week include 25 study visit .</brief_summary>
	<brief_title>A Study ALKS 3831 Adults With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>ALKS-33</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Age 18 50 year , inclusive Body mass index ( BMI ) 1730 kg/m2 , inclusive Diagnosis schizophrenia clinically stable Initiated 1st antipsychotic treatment within past 12 month and/or symptom last &lt; 2 year Current diagnosis alcohol drug use disorder , moderate severe Clinically significant unstable medical illness , condition , disorder Pregnant breastfeeding Significant change diet exercise regimen plan join weight management program study Opioid medication take within 14 day and/or need take opioid medication study period History hypersensitivity intolerance olanzapine Use olanzapine , clozapine , mesoridazine , chlorpromazine , thioridazine 1 week past year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Samidorphan</keyword>
	<keyword>Alkermes</keyword>
</DOC>